Mr. Chair, the honourable member raises a very good question about public interest as compared to individual privacy interests. There's no one answer that does it for all. I think in those kinds of contexts you would have to set up the legislation framework. If you're trying to monitor something as important as adverse drug reactions to drugs being administered to a large population, it would be necessary for the regulatory agency to have as much personal information as it needs to adequately monitor the drug; otherwise, there are going to be unsafe drugs on the market.
